Ebola Update in West Africa {#s1}
===========================

(Prepared by the Section Editor)---There were 3 new confirmed cases of Ebola virus disease reported in the week ending 18 October 2015, and 3 new cases in the week ending 25 October, all of which were reported in Guinea. There have been no new cases in Sierra Leone since the week ending 13 September, and no new cases in Liberia since 12 July.

Rebiotix Receives Breakthrough Therapy Designation for RBX2660 for the Treatment of Recurrent *Clostridium difficile* Infection {#s2}
===============================================================================================================================

12 October 2015 (PR Newswire)---Rebiotix Inc today announced that the US Food and Drug Administration (FDA) has designated its lead Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough Therapy for the treatment of recurrent *Clostridium difficile* infection (CDI). MRT is the Rebiotix drug platform for delivering healthy, live, human-derived microbes into a sick patient\'s intestinal tract to treat disease.

Studies have shown that most cases of CDI infection occur after the normal microorganisms that reside in the gut have been disrupted by antibiotic use. Restoring the balance of microbes is thought to be key to breaking the cycle of recurrence. Lead Rebiotix product, RBX2660, is targeted at treating recurrent CDI.

According to the FDA, Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

***Editorial comment.*** RBX2660 (microbiota suspension) is an intestinal microbe preparation for a ready-to-use enema. In one study of multirecurrent CDI, 34 patients received at least 1 dose of RBX2660 administered via enema. A second dose was permitted if CDI recurred \<8 weeks after the first dose. Overall efficacy of RBX2660, defined as the absence of CDI symptoms at 8 weeks after the last dose, was 87.1%.

FDA Warns of Serious Liver Injury Risk With Hepatitis C Treatments Viekira Pak and Technivie {#s3}
============================================================================================

22 October 2015 (FDA Safety Announcement)---The US Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, we are requiring the manufacturer to add new information about this safety risk to the drug labels.

Our review of adverse events reported to the FDA Adverse Event Reporting System (FAERS) database and to the manufacturer of these medicines, AbbVie, identified cases of hepatic decompensation and liver failure in patients with underlying liver cirrhosis who were taking these medicines. These serious outcomes were reported mostly in patients taking Viekira Pak who had evidence of advanced cirrhosis even before starting treatment with it.

Since the approvals of Viekira Pak in December 2014 and Technivie in July 2015, at least 26 worldwide cases submitted to FAERS were considered to be possibly or probably related to Viekira Pak or Technivie. In most of the cases, liver injury occurred within 1 to 4 weeks of starting treatment. FAERS includes only reports submitted to FDA, so there are likely additional cases about which we are unaware.

More Than 400 Dead in Southeast Congo Measles Outbreak---United Nations {#s4}
=======================================================================

19 October 2015 (Reuters \[Aaron Ross\])---A measles outbreak in the Democratic Republic of Congo\'s copper-mining southeast has killed 428 people and infected about 30 000 since the start of the year, the United Nations said.

More than 100 deaths and 10 000 additional cases have been recorded since mid-August, when the United Nations committed \$2.4 million to fight the outbreak in the former province of Katanga, which was recently divided into 4 \[administrative divisions\].

The outbreak is the country\'s worst since 2010--2011, when 1085 people died and about 77 000 were infected in Katanga.

Mortality rates from measles can be as high as 20% in poor countries, according to medical charity Médecins Sans Frontières, even though it only costs about \$1 to vaccinate a child.

The World Health Organization warned last November that progress toward wiping out measles has stalled worldwide due to poor vaccine coverage.
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***Editorial comment.*** This should be required reading for the antivaccination groups. For comparison, there were approximately 500 000 cases reported annually with 500 deaths a year in the United States prior to vaccine use (prior to 1963).

WHO Experts Signal Victory Over 1 of 3 Polio Strains {#s5}
====================================================

23 October 2015 (Reuters \[Tom Miles\])---The world should stop vaccinating children against 1 of the 3 strains of the polio virus, a group of health experts has advised the World Health Organization (WHO).

Currently, the primary tool against polio is an oral vaccine, which is directed against all 3 types of polio. The group is now recommending switching to a vaccine that only targets types 1 and 3, as type 2 has not been detected since 1999 and use of the vaccine itself can occasionally, inadvertently, aid the spread of the disease in countries with poor vaccine coverage.

A global vaccination campaign has all but beaten all 3 types of the wild polio virus, with only Pakistan and Afghanistan reporting cases this year.

But people who are vaccinated excrete the virus, putting those who have not been vaccinated at risk of catching it. Vaccine-derived cases have recently popped up in places with low vaccine coverage, such as Laos, Ukraine, Madagascar, and Guinea.

Hamid Jafari, director of polio eradication at the WHO, said the eventual goal was to phase out the type 1 and type 3 vaccines as well and to switch globally to inactivated vaccines, which are more costly and need to be injected rather than swallowed, but don\'t carry the risk of spreading the virus.

"We need at least 3 years of no wild polio virus circulation and good surveillance for the Global Commission (for the Certification of Poliomyelitis Eradication) to certify eradication of wild polio virus," he said.

"We haven\'t seen type 3 wildtype in over 3 years. Hopefully very soon we will stop seeing wild type 1," Abramson said.
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*Mycobacterium chelonae* Eye Infections Associated With Humidifier Use in an Outpatient LASIK Clinic---Ohio, 2015 {#s6}
=================================================================================================================

(MMWR 64:1177, 2015)---Laser-assisted in situ keratomileusis (LASIK) eye surgery is typically performed in an outpatient setting and involves the use of a machine-guided laser to reshape the lens of the eye to correct vision irregularities. Clinic A is an ambulatory surgery center that performs this procedure on 1 day each month. On 5 February 2015, the Toledo--Lucas County Health Department (TLCHD) in Ohio was notified of eye infections in 2 of the 6 patients who had undergone LASIK procedures at clinic A on 9 January 2015. The 2 patients experienced eye pain after the procedures and received diagnoses of infection with *Mycobacterium chelonae*, an environmental organism found in soil and water.

Clinic A subsequently performed 18 LASIK procedures on 13 February 2015. Two of these 18 patients experienced eye pain in early March 2015 and were determined to have laboratory-confirmed *M. chelonae.*

Although TLCHD staff reported that they did not observe obvious lapses in medication preparation or hand hygiene, they did note that clinic A used 2 humidifiers to maintain the 40%--50% relative humidity recommended by the manufacturer of the laser device used in the LASIK procedures. These cold air, reservoir style, retail humidifiers were filled with tap water and located in the operating room close to where patients were situated during the procedures. Both humidifiers contained an internal reservoir that held water during use. One of these devices used an ultrasonic nebulizer to produce a mist, whereas the other passed dry inlet air over a saturated wick.

Laboratory testing performed by the Centers for Disease Control and Prevention isolated *M. chelonae* from the water reservoir of the misting humidifier. Pulsed-field gel electrophoresis results indicated that 3 of the 4 patient isolates and the humidifier isolate were indistinguishable; the isolate from the fourth patient was closely related (\>95% similarity).

This outbreak was likely caused by the use of a consumer-grade misting humidifier that had been contaminated with *M. chelonae*.

World Health Chief Says US, Saudi Arabia Discussing MERS Vaccine {#s7}
================================================================

20 October 2015 (Reuters \[Tom Miles\])---The United States and Saudi Arabia may prepare a vaccine for Middle East respiratory syndrome (MERS) to try and head off the next outbreak of the disease, Margaret Chan, the head of the World Health Organization, said.

The facts behind the coronavirus that causes MERS have been slow to emerge, partly due to a secretive response in Saudi Arabia. Chan asked, "Is it just in camels? Or in other animals? Is there an available early version of the vaccine, where more work needs to be done? Do we need a vaccine for camels? These are questions we are discussing."

The transmission of MERS in Saudi hospitals and a MERS outbreak in South Korea showed that infection control standards were not being adhered to, she said, adding this was one of many examples of countries not sticking to their promises.

Many MERS patients have been health workers who caught the disease when sufferers came to hospital for treatment.
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